NZ603527A - Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules - Google Patents
Vaccines comprising cholesterol and cpg as sole adjuvant - carrier moleculesInfo
- Publication number
- NZ603527A NZ603527A NZ603527A NZ60352711A NZ603527A NZ 603527 A NZ603527 A NZ 603527A NZ 603527 A NZ603527 A NZ 603527A NZ 60352711 A NZ60352711 A NZ 60352711A NZ 603527 A NZ603527 A NZ 603527A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cholesterol
- vaccines
- cpg
- carrier molecules
- sole adjuvant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/265—Infectious rhinotracheitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34924410P | 2010-05-28 | 2010-05-28 | |
PCT/IB2011/052347 WO2011148356A1 (en) | 2010-05-28 | 2011-05-27 | Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ603527A true NZ603527A (en) | 2014-10-31 |
Family
ID=44626939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ603527A NZ603527A (en) | 2010-05-28 | 2011-05-27 | Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules |
Country Status (22)
Country | Link |
---|---|
US (1) | US10456463B2 (da) |
EP (1) | EP2575878B1 (da) |
JP (3) | JP2011251963A (da) |
KR (1) | KR101528021B1 (da) |
CN (1) | CN103025351B (da) |
AU (2) | AU2011259718B2 (da) |
BR (1) | BR112012030337B1 (da) |
CA (1) | CA2800158C (da) |
CL (1) | CL2012003299A1 (da) |
DK (1) | DK2575878T3 (da) |
ES (1) | ES2683316T3 (da) |
HR (1) | HRP20181039T1 (da) |
HU (1) | HUE038894T2 (da) |
LT (1) | LT2575878T (da) |
MX (1) | MX347471B (da) |
NZ (1) | NZ603527A (da) |
PL (1) | PL2575878T3 (da) |
PT (1) | PT2575878T (da) |
RS (1) | RS57428B1 (da) |
SI (1) | SI2575878T1 (da) |
WO (1) | WO2011148356A1 (da) |
ZA (1) | ZA201208837B (da) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
SI2759306T1 (sl) * | 2008-12-09 | 2016-05-31 | Coley Pharmaceutical Group, Inc. | Imunostimulacijski oligonukleotidi |
US9314519B2 (en) * | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
EP3542819B1 (en) * | 2013-05-14 | 2021-08-18 | Zoetis Services LLC | Novel vaccine compositions comprising immunostimulatory oligonucleotides |
ES2750608T3 (es) | 2013-07-25 | 2020-03-26 | Exicure Inc | Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico |
JP6586083B2 (ja) * | 2013-09-19 | 2019-10-02 | ゾエティス・サービシーズ・エルエルシー | 油性アジュバント |
AU2014337452A1 (en) | 2013-10-17 | 2016-04-21 | Zoetis Services Llc | Methods and compositions for treatment of S. equi infection |
BR112016012127A2 (pt) * | 2013-11-26 | 2017-09-26 | Zoetis Services Llc | composições para a indução da resposta imunológica |
KR102290205B1 (ko) | 2014-06-04 | 2021-08-20 | 엑시큐어, 인크. | 예방 또는 치료 용도를 위한 리포솜성 구형 핵산에 의한 면역 조절인자의 다가 전달 |
KR20170097116A (ko) * | 2015-01-16 | 2017-08-25 | 조에티스 서비시즈 엘엘씨 | 구제역 백신 |
US10456459B2 (en) * | 2015-07-20 | 2019-10-29 | Zoetis Services Llc | Liposomal adjuvant compositions |
ES2878475T3 (es) * | 2015-07-20 | 2021-11-18 | Zoetis Services Llc | Composiciones adyuvantes liposomales |
JP7076798B2 (ja) | 2015-09-09 | 2022-05-30 | 清華大学 | 効果的なワクチンアジュバントとするメバロン酸経路の阻害剤 |
CN107149671B (zh) * | 2016-03-03 | 2021-02-05 | 郭文江 | 一种药物组合物及其应用 |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
SG11202004773SA (en) | 2017-12-15 | 2020-06-29 | Bayer Animal Health Gmbh | Immunostimulatory compositions |
BR112022000347A2 (pt) * | 2019-07-12 | 2022-04-12 | Res Found Dev | Vacinas de ehrlichia e composições imunogênicas |
IT202100014747A1 (it) * | 2021-06-07 | 2022-12-07 | Consiglio Nazionale Ricerche | Derivati sterolici come nuovi ligandi del recettore dectina-1 nel trattamento terapeutico di patologie correlate a tale recettore |
CN115645417A (zh) * | 2022-10-17 | 2023-01-31 | 武汉轻工大学 | 鹅去氧胆酸在制备治疗或预防猪病毒性腹泻的药物或饲料添加剂中的应用 |
CN118059219B (zh) * | 2024-04-19 | 2024-06-25 | 西南交通大学 | 一种肥胖相关乳腺癌的个性化核酸疫苗及其制备方法 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
JP2547714B2 (ja) | 1981-10-23 | 1996-10-23 | モルキユラ− バイオシステムズ インコ−ポレテツド | オリゴヌクレオチド治療剤及びその製法 |
DE4321946A1 (de) | 1993-07-01 | 1995-01-12 | Hoechst Ag | Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
ATE328890T1 (de) * | 1994-07-15 | 2006-06-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
GB9718901D0 (en) * | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
DK1104306T3 (da) | 1998-08-10 | 2006-05-22 | Antigenics Inc | Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf |
FR2783170B1 (fr) * | 1998-09-11 | 2004-07-16 | Pasteur Merieux Serums Vacc | Emulsion immunostimulante |
GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
JP2003510290A (ja) | 1999-09-27 | 2003-03-18 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 免疫刺激核酸誘導インターフェロンに関する方法 |
CN1301572A (zh) * | 1999-10-28 | 2001-07-04 | 上海生物制品研究所 | 用于疫苗的佐剂组合物 |
US7129222B2 (en) * | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
EP1446162B1 (en) | 2001-08-17 | 2008-10-15 | Coley Pharmaceutical GmbH | Combination motif immune stimulatory oligonucleotides with improved activity |
GB0123580D0 (en) | 2001-10-01 | 2001-11-21 | Glaxosmithkline Biolog Sa | Vaccine |
MXPA04003900A (es) * | 2001-11-07 | 2004-07-08 | Cytos Biotechnology Ag | Disposiciones de antigenos para el tratamiento de enfermedades oseas. |
JP2005526497A (ja) * | 2002-02-04 | 2005-09-08 | ビオミラ,インコーポレーテッド | 免疫刺激性、共有結合性脂質化オリゴヌクレオチド |
KR20050052467A (ko) * | 2002-08-12 | 2005-06-02 | 다이나박스 테크놀로지 코퍼레이션 | 면역조절 조성물, 이의 제조방법 및 이의 이용방법 |
JP2007516219A (ja) * | 2003-05-07 | 2007-06-21 | アヴェンティス パストゥール インコーポレイテッド | 髄膜炎菌ワクチン接種に対する免疫原性の増強の方法 |
WO2005021726A2 (en) * | 2003-08-28 | 2005-03-10 | The Immune Response Corporation | Immunogenic hiv compositions and related methods |
GB0323965D0 (en) * | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
US20050175630A1 (en) * | 2003-12-23 | 2005-08-11 | Eyal Raz | Immunogenic compositions and methods of use thereof |
WO2005107797A1 (en) * | 2004-03-09 | 2005-11-17 | Chiron Corporation | Influenza virus vaccines |
CA2557443A1 (en) * | 2004-03-12 | 2005-09-29 | Hybridon, Inc. | Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide |
AU2005333126A1 (en) * | 2004-07-18 | 2006-12-21 | Csl Limited | Methods and compositions for inducing innate immune responses |
ATE521621T1 (de) * | 2004-11-29 | 2011-09-15 | Changchun Huapu Biotechnology Co Ltd | Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans |
EP1849780A1 (en) * | 2006-04-21 | 2007-10-31 | De Staat der Nederlanden, vert. door de minister van VWS | Vaccine against nicotine addiction |
AU2007268534B2 (en) * | 2006-05-31 | 2011-07-14 | Osaka University | Immunostimulatory oligonucleotide and pharmaceutical application thereof |
PT2078080E (pt) | 2006-09-27 | 2015-09-18 | Coley Pharm Gmbh | Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada |
MX2009012482A (es) * | 2007-05-17 | 2009-12-02 | Coley Pharm Group Inc | Oligonucleotidos de clase a con potencia inmunoestimuladora. |
CA2710983A1 (en) * | 2007-12-27 | 2009-10-01 | The Ohio State University Research Foundation | Lipid nanoparticle compositions and methods of making and using the same |
WO2009156960A2 (en) * | 2008-06-27 | 2009-12-30 | Pfizer Inc. | Novel adjuvant compositions |
-
2011
- 2011-05-27 DK DK11727536.2T patent/DK2575878T3/da active
- 2011-05-27 BR BR112012030337-6A patent/BR112012030337B1/pt active IP Right Grant
- 2011-05-27 HU HUE11727536A patent/HUE038894T2/hu unknown
- 2011-05-27 PL PL11727536T patent/PL2575878T3/pl unknown
- 2011-05-27 WO PCT/IB2011/052347 patent/WO2011148356A1/en active Application Filing
- 2011-05-27 PT PT11727536T patent/PT2575878T/pt unknown
- 2011-05-27 RS RS20180784A patent/RS57428B1/sr unknown
- 2011-05-27 MX MX2012013731A patent/MX347471B/es active IP Right Grant
- 2011-05-27 NZ NZ603527A patent/NZ603527A/en unknown
- 2011-05-27 KR KR1020127033947A patent/KR101528021B1/ko active IP Right Grant
- 2011-05-27 JP JP2011118735A patent/JP2011251963A/ja not_active Withdrawn
- 2011-05-27 CA CA2800158A patent/CA2800158C/en active Active
- 2011-05-27 US US13/699,997 patent/US10456463B2/en active Active
- 2011-05-27 CN CN201180036906.3A patent/CN103025351B/zh active Active
- 2011-05-27 AU AU2011259718A patent/AU2011259718B2/en active Active
- 2011-05-27 SI SI201131538T patent/SI2575878T1/sl unknown
- 2011-05-27 ES ES11727536.2T patent/ES2683316T3/es active Active
- 2011-05-27 LT LTEP11727536.2T patent/LT2575878T/lt unknown
- 2011-05-27 EP EP11727536.2A patent/EP2575878B1/en active Active
- 2011-05-27 JP JP2013513022A patent/JP6034285B2/ja active Active
-
2012
- 2012-11-22 ZA ZA2012/08837A patent/ZA201208837B/en unknown
- 2012-11-26 CL CL2012003299A patent/CL2012003299A1/es unknown
-
2016
- 2016-05-31 AU AU2016203611A patent/AU2016203611B2/en active Active
- 2016-09-06 JP JP2016173482A patent/JP6133482B2/ja active Active
-
2018
- 2018-07-05 HR HRP20181039TT patent/HRP20181039T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ603527A (en) | Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules | |
NZ737757A (en) | Peptide oligonucleotide conjugates | |
MX2013004338A (es) | Secuencias de repeticiones palindromicas cortas separadas regularmente agrupadas-cas (crisp-cas). | |
MX2021006342A (es) | Mutantes de virus de influenza y usos para los mismos. | |
WO2015066634A3 (en) | Optimal soybean loci | |
WO2013026740A3 (en) | Methods and means to modify a plant genome | |
EP3698631A3 (en) | Methods of delivering oligonucleotides to immune cells | |
UA103316C2 (uk) | Вакцини на базі флавівірусів з дефектною реплікацією і вектори для одержання вакцин | |
MX343048B (es) | Oligodesoxinucleotidos inmunoestimulantes. | |
EP2569330A4 (en) | CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF | |
MX2013013800A (es) | Oligodesoxinucleotidos inmunoestimuladores. | |
IL214385A0 (en) | Inactivated dengue virus vaccine with aluminium-free adjuvant | |
IN2014DN00078A (da) | ||
NZ606087A (en) | Influenza vaccine | |
MX348785B (es) | Metodos y medios para modificar un genoma vegetal en un sitio preseleccionado. | |
MX2013003245A (es) | Vacuna contra virus de diarrea viral de bovinos. | |
WO2013052095A3 (en) | Vaccine | |
AP2010005446A0 (en) | Inactivated live-attenuated bluetongue virus vaccine. | |
WO2014008475A3 (en) | Compositions and methods related to viral vaccines | |
MX350718B (es) | Vacuna de rinitis equina. | |
MX2011005281A (es) | Vacuna marcadora de salmonella. | |
WO2013049535A3 (en) | Influenza vaccine | |
WO2012003030A3 (en) | Methods of identifying & using anti-viral compounds | |
AP2010005333A0 (en) | Vaccine comprising a ribosomal protein extract (RPE) and optionally a thi-promoting adjuvant. | |
GB0818080D0 (en) | Immunogenic peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ASS | Change of ownership |
Owner name: ZOETIS BELGIUM S.A., BE Effective date: 20130426 |
|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2016 BY BALDWINS INTELLECTUAL PROPERTY Effective date: 20150302 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2017 BY THOMSON REUTERS Effective date: 20160415 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2018 BY THOMSON REUTERS Effective date: 20170421 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2019 BY THOMSON REUTERS Effective date: 20180418 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2020 BY THOMSON REUTERS Effective date: 20190417 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2021 BY THOMSON REUTERS Effective date: 20200417 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2022 BY THOMSON REUTERS Effective date: 20210403 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2023 BY THOMSON REUTERS Effective date: 20220402 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2024 BY THOMSON REUTERS Effective date: 20230403 |